**About PharmaCare**
B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

**Details of Drug Reviewed**

<table>
<thead>
<tr>
<th>Drug</th>
<th>apomorphine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brand Name</td>
<td>Movapo™</td>
</tr>
<tr>
<td>Dosage Form</td>
<td>10 mg/mL pre-filled pen</td>
</tr>
<tr>
<td>Manufacturer</td>
<td>Paladin Labs Inc.</td>
</tr>
<tr>
<td>Submission Type</td>
<td>New Submission</td>
</tr>
</tbody>
</table>

**Use Reviewed**
Advanced Parkinson’s disease

**Common Drug Review (CDR)**
Yes, CDR recommended: to Reimburse with clinical criteria and/or conditions. Visit the CDR website for more details: [https://cadth.ca/sites/default/files/cdr/complete/SR0527_Movapo_complete-Jan-25-18.pdf](https://cadth.ca/sites/default/files/cdr/complete/SR0527_Movapo_complete-Jan-25-18.pdf)

**Drug Benefit Council (DBC)**
The DBC met on February 19, 2018, and considered various inputs including: clinical and pharmacoeconomic evidence review material and the recommendation from the Canadian Drug Expert Committee (CDEC). No patients, caregivers or patient groups submitted input to the DBC for review. However, the DBC considered patient Input provided to the CDR, as well as Clinical Practice Reviews from one specialist and one general practitioner; lastly, the DBC considered an Other Drug Agencies Review Recommendations provided by CADTH.

**Drug Coverage Decision**
Limited Coverage Benefit. Access the apomorphine criteria from: [www.gov.bc.ca/pharmacarespecialauthority](http://www.gov.bc.ca/pharmacarespecialauthority)

**Date**
November 26, 2019

**Reasons**
Drug coverage decision is consistent with the DBC recommendation.
- Apomorphine demonstrated some advantage over placebo with respect to improvement in motor function.
- At the submitted price apomorphine was not considered cost-effective by DBC.
• BC participated in the pan-Canadian Pharmaceutical Alliance (pCPA) negotiations with manufacturer and an agreement was reached.

Other Information

| None |

### The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council (DBC)](https://www.gov.bc.ca/additionalResources/pharmacare/dbc/) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review (CDR)](https://www.gov.bc.ca/additionalResources/pharmacare/cdr/)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit [The Drug Review Process in B.C. - Overview](https://www.gov.bc.ca/additionalResources/pharmacare/dbc/overview/) and [Ministry of Health - PharmaCare](https://www.gov.bc.ca/additionalResources/pharmacare/) for more information.

**This document is intended for information only.**

It does not take the place of advice from a physician or other qualified health care provider.